<DOC>
	<DOCNO>NCT02175355</DOCNO>
	<brief_summary>Primary : To identify dos Micardis® ( telmisartan ) , administer daily , effective placebo inferior HCTZ lower systolic blood pressure ( SBP ) patient isolate systolic hypertension ( ISH ) , assess dose response relationship antihypertensive effect telmisartan dose range 20 80 mg . Secondary : Target fall SBP , change baseline seat DBP . Safety tolerability Micardis® HCTZ patient ISH measure change physical examination , heart rate , laboratory parameter and/or 12-lead ECG , well incidence severity adverse event .</brief_summary>
	<brief_title>Efficacy Safety Angiotensin II Receptor Antagonist Micardis® ( Telmisartan ) Hydrochlorothiazide Management Patients With Isolated Systolic Hypertension ( ISH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<criteria>At least 35 year , less 85 year age Mean SBP ≥ 150 mm Hg mean DBP &lt; 90 mm Hg randomisation visit ( visit 2 ) , accord WHO definition ISH ( exclude subgroup borderline ISH ) Hypertensive patient current antihypertensive therapy able stop current treatment period 8 10 week without endanger health patient ( investigator 's discretion ) Ability provide write informed consent Premenopausal woman ( last menstruation ≤ 1 year prior start runin period ) : 1. surgically sterile ; and/or 2. nursing 3. childbearing potential practicing acceptable mean birth control NOT plan continue use method throughout study . Acceptable method birth control include oral , implantable injectable contraceptive Mean systolic blood pressure ≥ 180 mmHg randomization Visit 2 Known suspect secondary hypertension Hepatic and/or renal dysfunction define follow laboratory parameter : 1 . Serum glutamic pyruvate transaminase ( ALT ) serum glutamic oxaloacetic transaminase ( AST ) &gt; 2 time upper limit normal range 2 . Serum creatinine &gt; 1.8 mg/dl ( 159 µmol/l ) Bilateral renal artery stenosis ; renal artery stenosis solitary kidney , patient postrenal transplant one function kidney Clinically relevant hypokalemia hyperkalemia Uncorrected volume sodium depletion Primary aldosteronism Hereditary fructose intolerance Biliary obstructive disorder Symptomatic congestive heart failure Angina pectoris previous myocardial infarction Previous percutaneous transluminal coronary angioplasty coronary artery bypass craft Previous cerebrovascular accident hypertensive encephalopathy transient ischemic attack ( ) Current treatment antihypertensive agent , whether prescribed indication , safely stop ( investigator decision ) start runin period . Any pretreatment diuretic , ACE inhibitor angiotensin II receptor antagonist require extension runin period 2 4 week adequate washout Atrial fibrillation ( control otherwise ) clinically relevant cardiac arrhythmia determine clinical investigator Hemodynamically relevant aortic mitral valve stenosis , obstructive hypertrophic cardiomyopathy outflow obstruction leave ventricle Patients noninsulindependent diabetes mellitus require treatment oral hypoglycemics fail meet follow criterion history : 1 . Fasting blood glucose le 200 mg/dl ( 11.1 mmol/l ) 2 . Therapy stabilize least one month prior start placebo runperiod Patients diabetes mellitus require treatment insulin Patients previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensin II receptor antagonist Known drug alcohol dependency Any investigational therapy within one month signing informed consent form trial Known hypersensitivity component formulation telmisartan hydrochlorothiazide include allergy sulfonamide Concomitant use lithium cholestyramine colestipol resin ( potential drug interaction HCTZ ) Gout ( contraindication treatment HCTZ ) Any clinical condition , opinion principal investigator , would allow safe completion protocol safe administration telmisartan hydrochlorothiazide</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>